Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.

Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, Ivanova MI, Loo JA, Klärner FG, Schrader T, Stahl M, Bitan G, Bronstein JM.

Neurotherapeutics. 2012 Apr;9(2):464-76. doi: 10.1007/s13311-012-0105-1. Erratum in: Neurotherapeutics. 2012 Apr;9(2):486. Lakshmanan, Ravi [corrected to Lakshmanan, Rajeswari].

2.

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M.

J Neurol. 2009 Aug;256 Suppl 3:286-92. doi: 10.1007/s00415-009-5246-8. Review.

PMID:
19711118
3.

Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.

Amer DA, Irvine GB, El-Agnaf OM.

Exp Brain Res. 2006 Aug;173(2):223-33. Epub 2006 May 30. Review.

PMID:
16733698
4.

Neuropathology of synuclein aggregates.

Duda JE, Lee VM, Trojanowski JQ.

J Neurosci Res. 2000 Jul 15;61(2):121-7. Review.

PMID:
10878583
5.
6.

Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?

Kanaan NM, Manfredsson FP.

J Parkinsons Dis. 2012;2(4):249-67. doi: 10.3233/JPD-012138. Review.

7.

The remarkable conformational plasticity of alpha-synuclein: blessing or curse?

Deleersnijder A, Gerard M, Debyser Z, Baekelandt V.

Trends Mol Med. 2013 Jun;19(6):368-77. doi: 10.1016/j.molmed.2013.04.002. Epub 2013 May 3. Review.

PMID:
23648364
8.
9.

Calcium: Alpha-Synuclein Interactions in Alpha-Synucleinopathies.

Rcom-H'cheo-Gauthier AN, Osborne SL, Meedeniya AC, Pountney DL.

Front Neurosci. 2016 Dec 20;10:570. doi: 10.3389/fnins.2016.00570. eCollection 2016. Review.

Supplemental Content

Support Center